[MicroRNA Expression Profiling of Diffuse Large B-Cell Lymphoma].

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers that differ in pathogenesis and prognosis. The main methods of treating NHL include chemotherapy, immunochemotherapy, and radiation therapy. However, a significant proportion of these tumors are chemoresistant or rapidly recur after a short chemotherapy-induced remission. In this regard, the search for alternative cytoreductive therapeutic methods is relevant. Aberrant expression of microRNA (miRNA) is one of the mechanisms responsible for the emergence and progression of malignant lymphoid neoplasms. We analyzed the profile of miRNA expression in the biopsy material from lymph nodes affected by diffuse large B-cell lymphoma (DLBCL). The key material of the study was histological preparations of lymph nodes obtained by excisional diagnostic biopsy and treated using conventional histomorphological formalin fixation methods. The study group consisted of patients with DLBCL (n = 52); the control group consisted of patients with reactive lymphadenopathy (RL) (n = 40). It was shown that the miR-150 expression level in DLBCL was reduced by more than 12 times (p = 3.6 x 10^(-15)) compared with RL. Bioinformatics analysis revealed the involvement of miR-150 in the regulation of hematopoiesis and lymphopoiesis. The data we obtained allow us to consider miR-150 as a promising therapeutic target with great potential in clinical practice.

MicroRNAs in the Myelodysplastic Syndrome.

The myelodysplastic syndrome (MDS) holds a special place among blood cancers, as it represents a whole spectrum of hematological disorders with impaired differentiation of hematopoietic precursors, bone marrow dysplasia, genetic instability and is noted for an increased risk of acute myeloid leukemia. Both genetic and epigenetic factors, including microRNAs (miRNAs), are involved in MDS development. MicroRNAs are short non-coding RNAs that are important regulators of normal hematopoiesis, and abnormal changes in their expression levels can contribute to hematological tumor development. To assess the prognosis of the disease, an international assessment system taking into account a karyotype, the number of blast cells, and the degree of deficiency of different blood cell types is used. However, the overall survival and effectiveness of the therapy offered are not always consistent with predictions. The search for new biomarkers, followed by their integration into the existing prognostic system, will allow for personalized treatment to be performed with more precision. Additionally, this paper explains how miRNA expression levels correlate with the prognosis of overall survival and response to the therapy offered.

[Quantitative and functional characteristics of T-lymphocytes and monocytes in lymphosarcoma patients at various stages of the neoplastic process]. / Kolichestvennaia i funktsional'naia kharakteristika T-limfotsitov i monotsitov u bol'nykh limfosarkomoi na raznykh stadiiakh opukholevogo protsessa.

IKO monoclonal antibodies were used to study peripheral blood mononuclear types in 92 patients with various histomorphological types of diffuse lymphosarcoma at various stages of tumorous process. Absolute counts of CD7 and CD5 cells (T cells) were found reducing as was CD4 cell (T helpers) level as the disease progressed. CD8 cell (T suppressors) count reliably increased only in the phase of lymphoblastic lymphosarcoma leukemic degeneration. A group of patients with stage IV lymphoblastic lymphosarcoma was detected with drastically increased counts of mononuclears carrying mature T cell markers. Clinical course of the disease in these patients was characterized by the highest malignancy degree and metastatic involvement of the central nervous system. Examination of peripheral blood monocyte/macrophage ratio in the same patient population (n = 26) revealed reduced Fc receptor expression, EA phagocytosis, and increased levels of circulating immune complexes, these shifts augmenting with the tumor progress. The results may be valuable for prediction of lymphosarcoma course and for immunocorrection.

[Structure and function of erythrocytes in lymphomas]. / Struktura i funktsiia éritrotsitov pri limfomakh.

Significant changes have been recorded in the concentration of sulfhydryl groups, histidine, lipoproteins, catalase activity, saponin resistance, and kinetics of chemiluminescent responses of red blood cells in lymphoma patients. Lymphosarcoma is characterized by changes in the structure and function of red blood cells at the early stage of the process, whereas in lymphogranulomatosis changes are observed with the disease progressing, when pronounced signs of tumor intoxication are noted and anemia is present. In lymphosarcoma patients an increase of peripheral blood mononuclears is recorded which expresses the erythroid differentiating antigens with the use of monoclonal antibodies against glycophorin A (ZAE-3) and human erythroblast antigen AG-EB (HAE-9). In lymphogranulomatosis patients it was not detected.

[Expression of erythroid differentiation antigens on mononuclear cells of peripheral blood in neoplastic progression of non-Hodgkin's malignant lymphoma]. / Ekspressiia éritroidnykh differentsirovochnykh antigenov na mono- nuklearakh perifericheskoi krovi pri opukholevoi progressii nekhodzhkinskikh zlokachestvennykh limfom.

High level expression of erythroid differentiation antigens on peripheral blood mononuclear cells associated with increased BFUe number has been identified in a malignant lymphoma patient. A possible pathogenetic role of such disturbance in leukemogenesis has been considered.

[The expression of lymphopoietic differentiation antigens on the membrane of the peripheral blood mononuclear cells in lymphosarcoma tumor progression]. / Izuchenie ékspressii differentsirovochnykh antigenov limfopoéza na membrane mononuklearov perifericheskoi krovi pri opukholevoi progressii limfosarkom.

Monoclonal antibodies were used in the indirect immunofluorescence test to assay the antigenic features of lymphoid cells in patients with lymphosarcoma. Some patients with progression of lymphoblastic lymphoma showed an increased content of T lymphocyte expressing early activation antigens, antigens of early hemopoietic progenitors, and CALLA-antigens.